Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195

Read also

Merck KGaA

Merck KGaA eyes new Parkinson’s disease assets with $3bn Valo partnership

FDA Approves Perioperative Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC

FDA Approves Perioperative Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC

ALS oral therapy

ALS oral therapy slows disease progression in preclinical testing

Alvotech and Advanz

Alvotech and Advanz announce EC approval for Gobivaz biosimilar